Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05478538 · ClinicalTrials.gov registry record
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
A clinical trial of NSCLC (Non-small Cell Lung Cancer) and Metastatic NSCLC - Non-Small Cell Lung Cancer, sponsored by Elephas.
- Recruiting
- Registry status
- 200
- Enrollment target
- 7
- Study locations
NCT05478538: Recruiting study of NSCLC (Non-small Cell Lung Cancer) and Metastatic NSCLC - Non-Small Cell Lung Cancer, sponsored by Elephas.
NCT05478538 is a study of NSCLC (Non-small Cell Lung Cancer) and Metastatic NSCLC - Non-Small Cell Lung Cancer that is actively recruiting participants, run by Elephas. The registered enrollment target is 200 participants, below the 332-participant average among 10 other NSCLC (Non-small Cell Lung Cancer) trials with a reported enrollment target (40% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05478538, a study of NSCLC (Non-small Cell Lung Cancer) and Metastatic NSCLC - Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Elephas.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.
Primary Outcome
The ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform will be determined using in-vivo RECIST 1.1 as the reference method.
Conditions Studied
Interventions
- PROCEDURE Core Needle, Forceps, or Punch Biopsy
Study Locations (7)
Texas
- JPS Health Network - Fort Worth
- Baylor Scott & White Research Institute - Temple
California
- UCLA Medical Center - Los Angeles
Maryland
- James M Stockman Cancer Institute - Frederick
New York
- New York Cancer & Blood Specialists - Shirley
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Ohio
- Gabrail Cancer Center - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2026-12 |
What NCT05478538 shows while recruiting
NCT05478538 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 332-participant average among 10 other NSCLC (Non-small Cell Lung Cancer) trials with a reported enrollment target (40% lower).
The record links to 2 conditions, with NSCLC (Non-small Cell Lung Cancer) appearing as the primary indexed condition, and to 1 intervention - of which Core Needle, Forceps, or Punch Biopsy is the first listed.
NCT05478538 lists 7 locations in 6 states (Texas, California, Maryland).
Frequently Asked Questions
What is clinical trial NCT05478538 about?
NCT05478538 is a clinical study titled "Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform". The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.
What is the current status of trial NCT05478538?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2023-01-31. Estimated completion is 2026-12.
What conditions does trial NCT05478538 study?
This clinical trial studies the following conditions: NSCLC (Non-small Cell Lung Cancer), Metastatic NSCLC - Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05478538?
The interventions under investigation include: Core Needle, Forceps, or Punch Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT05478538?
This trial is sponsored by Elephas, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05478538 being conducted?
This trial has 7 study locations across California, Maryland, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NSCLC (Non-small Cell Lung Cancer)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05478538's enrollment target sits among peer trials
200 6th of 10 higher than 5 of 10 other NSCLC (Non-small Cell Lung Cancer) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NSCLC (Non-small Cell Lung Cancer) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RECRUITING · Phase 1
-
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
RECRUITING · Phase 1
-
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RECRUITING · Phase 1
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI